USA: Consumer Healthcare Pfizer Announces Strategic Restructuring of its Healthcare Businesses
Editor: Alexander Stark
Pfizer said that a range of options will be considered, including a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction.
Pfizer Consumer Healthcare is one of the largest OTC health care products businesses in the world.
(Source: Pixabay CC0)
New York/USA — Although the company may ultimately determine to retain the business, Pfizer is reviewing strategic alternatives for its Consumer Healthcare business.
Pfizer Consumer Healthcare is one of the largest OTC health care products businesses in the world with 2016 revenues of approximately $ 3.4 billion, operating in more than 90 countries globally. This business markets two of the ten top selling consumer healthcare brands globally — Centrum and Advil. In addition, the business has ten brands that each exceeded $ 100 million in 2016 sales, and several local brands that are top-ranked in their respective markets.
Ian Read, Pfizer Chairman and Chief Executive Officer said: “Although there is a strong connection between Consumer Healthcare and elements of our core biopharmaceutical businesses, it is also distinct enough from our core business that there is potential for its value to be more fully realized outside the company."
The company expects that any decision regarding strategic alternatives for Pfizer Consumer Healthcare would be made during 2018, adding that it does not plan to make any further statements about the strategic review process until a decision has been reached or upon the completion of the strategic review.
Unfold for details of your consent
Stand vom 23.03.2021
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.